Molecular Spectroscopic Photoacoustic Imaging for Breast Lesion Characterization
用于乳腺病变表征的分子光谱光声成像
基本信息
- 批准号:9181200
- 负责人:
- 金额:$ 19.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-01 至 2018-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAgeAnimalsAntibodiesAntibody FormationApplications GrantsBenignBindingBinding ProteinsBiodistributionBiological AssayBiopsyBlood CirculationBreast Cancer DetectionBreast Cancer Early DetectionBreast Cancer PatientBreast biopsyCallbackCancer DetectionCellsClinicalClinical TrialsConfocal MicroscopyContrast MediaDataDevelopmentDiagnosisDiseaseDyesFDA approvedFibronectinsFlow CytometryFluorescent DyesFoundationsFutureGoalsHalf-LifeHealth Care CostsHealthcare SystemsHistamine H3 ReceptorsHumanHuman Cell LineHyperplasiaImageImaging TechniquesIn VitroIndocyanine GreenInjection of therapeutic agentLesionLifeLigand BindingLigandsLightMalignant - descriptorMalignant NeoplasmsMammary Gland ParenchymaMammary UltrasonographyMammographyMethodologyModalityModelingMolecularMolecular TargetMonitorMouse Mammary Tumor VirusMusNoiseNoninfiltrating Intraductal CarcinomaOperative Surgical ProceduresOpticsPatientsPredictive ValueProspective StudiesProtein EngineeringProteinsProteolysisPublic HealthReceptor CellResearch ProposalsScaffolding ProteinSensitivity and SpecificitySignal TransductionSpecificitySpectrophotometryStagingSuccinimidesSurface Plasmon ResonanceTestingTimeTissuesTransgenic MiceTranslatingTranslationsUltrasonographyUnited StatesWomanabsorptionantibody conjugatebasebreast imagingbreast lesioncancer biomarkerscancer imagingclinically actionableclinically significantcontrast enhancedcostdesigndiagnostic accuracydosagefluorescence imagingfollow-upimaging modalityimprovedin vivolive cell imagingmalignant breast neoplasmmolecular imagingmortalitymouse modelnoveloverexpressionphotoacoustic imagingphysical propertypreventprototypereceptor mediated endocytosisresearch studyscaffoldscreeningsoundtechnique developmenttooltumoruptake
项目摘要
Breast cancer is the second deadliest cancer in women, and will claim more than 40,000 lives in the United
States in 2015 alone. Mammography is the first line imaging technique for early breast cancer detection, but the
presence of dense breast tissue decreases its diagnostic accuracy. Due to its widespread availability and
increased cancer detection rates, ultrasound is often performed as a second line test in women with dense breast
tissue. However, ultrasound results in many false positive findings with unnecessary biopsies with increased
associated health care costs. The goal of this research proposal is to develop an imaging approach that allows
accurate, non-invasive characterization of focal breast lesions into clinically actionable (follow-up with biopsy or
surgery is needed) and non-actionable lesions. We propose using spectroscopic photoacoustic (sPA) molecular
imaging combined with a new clinically-translatable contrast agent that can be incorporated into the current
clinical ultrasound imaging workflow. The new contrast agent will be developed by combining two clinically used
components: First, a human fibronectin-based binding ligand (FN3-scaffolds), similar versions of which have
been shown to be safe in patients; and second, the near-infrared fluorescent dye, indocyanine green (ICG),
which is FDA approved for IV injection in patients. The ICG-FN3-scaffold will be targeted at a recently identified
and validated breast cancer marker, B7-H3, which we have shown to be highly expressed in various types of
human breast cancer compared to normal breast tissue and benign breast lesions in patients. It will be
synthesized, tested, and optimized for its B7-H3 binding abilities in murine and human cell lines using flow
cytometry. Since ICG can undergo significant shifts in optical absorption spectra based on its bound state to
proteins, through live cell imaging experiments with confocal microscopy, we will assess whether B7-H3 receptor
mediated endocytosis of the contrast agent results in intracellular release of ICG with consecutive spectral shift
of its absorption spectrum. This shift could be leveraged to differentiate imaging signal from bound and non-
bound contrast agent, thereby increasing tumor to background signal. Finally, to test the ability of B7-H3-targeted
sPA molecular imaging to differentiate between clinically actionable and non-actionable lesions, a transgenic
mouse model (FVB/N Tg(MMTV/PyMT634Mul) of breast cancer development will be used. Animals at varying
ages, corresponding to different histopathological disease stages (normal, hyperplasia, DCIS, and breast
cancer), will be imaged with sPA following IV injection of B7-H3-targeted ICG-FN3 and a sPA imaging signal
threshold will be determined to allow differentiation of benign vs malignant lesions. This will be followed by a
prospective study to assess the diagnostic accuracy of B7-H3-targeted sPA to differentiate clinically actionable
from non-actionable lesions based on the sPA imaging signal in this model. Our study will lay the foundation for
a significant change to current clinical breast imaging practice by improving non-invasive characterization of focal
breast lesions, with the potential of substantially changing future management of breast cancer patients.
乳腺癌是女性第二大致命癌症,在美国将夺去4万多人的生命。
仅2015年一年。乳房X线摄影是早期乳腺癌检测的第一线成像技术,但
致密乳腺组织的存在降低了其诊断准确性。由于其广泛的可用性和
提高癌症检出率,超声检查通常作为致密乳腺妇女的二线检查
组织.然而,超声导致许多假阳性结果,不必要的活检,
相关的医疗保健费用。这项研究计划的目标是开发一种成像方法,
准确、非侵入性地将乳腺局灶性病变定性为临床可操作的(随访活检或
需要手术)和不可操作的损伤。我们建议使用光谱光声(sPA)分子
成像与新的临床可转换的造影剂相结合,
临床超声成像工作流程。新的造影剂将通过结合两种临床使用的
组分:首先,基于人纤连蛋白的结合配体(FN 3-支架),其类似版本具有
已被证明在患者中是安全的;第二,近红外荧光染料,吲哚菁绿色(ICG),
FDA批准用于患者静脉注射ICG-FN 3-支架将靶向最近鉴定的
和经验证的乳腺癌标志物B7-H3,我们已经证明它在各种类型的乳腺癌中高度表达。
人类乳腺癌患者与正常乳腺组织和良性乳腺病变患者相比。将
在小鼠和人细胞系中使用流式细胞仪合成、测试和优化其B7-H3结合能力
细胞仪由于ICG可以基于其结合态在光学吸收光谱中经历显著的位移,
蛋白质,通过活细胞成像实验与共聚焦显微镜,我们将评估是否B7-H3受体
造影剂的介导的内吞作用导致ICG的细胞内释放,伴随连续的光谱移位
它的吸收光谱。这种偏移可以被用来区分成像信号与结合和非结合信号。
结合造影剂,从而增加肿瘤对背景信号的影响。最后,测试B7-H3靶向的能力
sPA分子成像,以区分临床上可采取行动和不可采取行动的病变,转基因
将使用乳腺癌发展的小鼠模型(FVB/NTg(MMTV/PyMT 634 Mul))。动物在不同
年龄,对应于不同的组织病理学疾病阶段(正常、增生、DCIS和乳腺癌)
在IV注射B7-H3靶向的ICG-FN 3和sPA成像信号后,
将确定阈值以区分良性病变与恶性病变。这将是一个
一项前瞻性研究,旨在评估B7-H3靶向sPA的诊断准确性,以区分临床可行性
基于该模型中的sPA成像信号从不可操作的病变中分离。我们的研究将为
通过改善病灶的非侵入性表征,
乳腺病变,有可能大大改变乳腺癌患者的未来管理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Juergen Karl Willmann其他文献
Juergen Karl Willmann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Juergen Karl Willmann', 18)}}的其他基金
Quantification and monitoring inflammation in IBD with Molecular Ultrasound
用分子超声定量和监测 IBD 炎症
- 批准号:
8295923 - 财政年份:2012
- 资助金额:
$ 19.93万 - 项目类别:
Quantification and monitoring inflammation in IBD with Molecular Ultrasound
用分子超声定量和监测 IBD 炎症
- 批准号:
8690039 - 财政年份:2012
- 资助金额:
$ 19.93万 - 项目类别:
Quantification and monitoring inflammation in IBD with Molecular Ultrasound
用分子超声定量和监测 IBD 炎症
- 批准号:
8880188 - 财政年份:2012
- 资助金额:
$ 19.93万 - 项目类别:
Quantification and monitoring inflammation in IBD with Molecular Ultrasound
用分子超声定量和监测 IBD 炎症
- 批准号:
8521280 - 财政年份:2012
- 资助金额:
$ 19.93万 - 项目类别:
Molecular Ultrasound for Early Breast Cancer Detection
分子超声用于早期乳腺癌检测
- 批准号:
8704306 - 财政年份:2011
- 资助金额:
$ 19.93万 - 项目类别:
Molecular Ultrasound for Early Breast Cancer Detection
分子超声用于早期乳腺癌检测
- 批准号:
8115571 - 财政年份:2011
- 资助金额:
$ 19.93万 - 项目类别:
Molecular Ultrasound for Early Breast Cancer Detection
分子超声用于早期乳腺癌检测
- 批准号:
8510598 - 财政年份:2011
- 资助金额:
$ 19.93万 - 项目类别:
Early Detection of Pancreatic Cancer with Targeted Contrast-enhanced Ultrasound
靶向超声造影早期发现胰腺癌
- 批准号:
7739380 - 财政年份:2009
- 资助金额:
$ 19.93万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 19.93万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 19.93万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 19.93万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 19.93万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 19.93万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 19.93万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 19.93万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 19.93万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 19.93万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 19.93万 - 项目类别:
Directed Grant